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Small Synthetic Ligands ofthe Cholecystokinin-B/Gastrin Receptor
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The gastric cholecystokinin-B/gastrin receptor (CCK-BR) is a key regulator of
enterochromaffin-like cell function and proliferation. Over the last decade, a
numberofsmall non-peptide CCK-BR "antagonists" have been discovered. Here,
we demonstrate that some ofthesenon-peptide ligands in factpossess significant
ability to activate the human CCK-BR, and are, therefore, more properly cate-
gorized as partial agonists. When tested in COS-7 cells transiently expressing
the recombinant human CCK-BR, saturating concentrations of the small "pep-
toid" ligands PD 135,158 andPD 136,450 stimulated inositol phosphate formation
to 23 and 43 percent, respectively, ofthe maximum response induced by a con-
siderably larger endogenous peptide agonist, cholecystokinin octapeptide. In
contrast, the benzodiazepine-derived CCK-BR ligand, YM022, acted as a "true"
high-affinity antagonist ofcholecystokinin-induced inositol phosphate formation
(pA2 = 9.69). Consistent with recent findings in animal experiments, our data
reveal that small synthetic ligands have thepotential to function as eitherCCK-BR
agonists or antagonists. These dual properties of synthetic molecules must be
considered when evaluating candidate drugs for human disease.
INTRODUCTION
The cholecystokinin-B/gastrin receptor (CCK-BR)b is a seven transmembrane domain
protein that modulates multiple functions in both the gastrointestinal tract and the brain
[1, 2]. In the stomach, the CCK-BR has been well established to stimulate gastric acid
secretion and mucosal cell growth [3, 4]. In particular, there is strong evidence suggesting
that this receptor can induce the proliferation ofenterochromaffin-like cells [5]. In the brain,
the CCK-BR has been implicated in triggering anxiety attacks and may also modulate the
perception ofpain [6-9].
The CCK-BR is endogenously activated by structurally related endogenous peptide
hormones and neurotransmitters, including the heptadecapeptide gastrin (G-17) and the
octapeptide cholecystokinin (CCK-8). These peptides bind to the CCK-BR with affinities
in the subnanomolar range and lead to the activation ofphospholipase-C as a major second
messenger pathway. Phospholipase-C, in turn, initiates the breakdown ofmembranephospho-
lipids to inositol phosphate metabolites and the subsequent release ofintracellular Ca2+ as
early signal transduction events [2, 4].
High affinity binding ofendogenous peptide ligands to the CCK-BR is mimicked by
considerably smaller synthetic molecules, which have been developed in an attempt to
generate clinically useful CCK-BR antagonists. Such compounds include (i) "peptoid"
derivatives that retain minimal structural features ofthe endogenous peptide agonists [10,
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11], and (ii) achemically different class ofmolecules with a common benzodiazepine-like
backbone [12, 13]. Interestingly, we have recently discovered that these putative non-peptide
antagonists occupy a ligand "pocket" within the transmembrane domains ofthe CCK-BR,
similar to that described for biogenic amine receptors [14].
Given this considerable overlap of binding determinants, we speculated whether
small synthetic CCK-BR ligands might have similar agonist potential as biogenic amines
of similar size [15]. In fact, this hypothesis is supported by recent reports that "peptoid"
compounds may act as partial agonists ofthe CCK-BR in vivo, with the ability to stimulate
gastric acid secretion and ECL cell activation [16, 17]. In contrast, other investigators
have been unable to detect any intrinsic activity of"peptoids" in the rat [18-21] and have,
therefore, classified these compounds as antagonists both by in vivo and in vitro assays.
Given these contradictory results, the postulated agonistpotential of"peptoid" compounds
remains to be further clarified, in particular when interacting with the human CCK-BR.
Using a simplified test system, we have, therefore, studied the abilities ofseveral ben-
zodiazepine-derived and "peptoid" ligands to stimulate the recombinant human CCK-BR
when transiently expressed in COS-7 cells. These experiments clearly reveal considerable
agonist properties of small synthetic CCK-BR ligands, reflected by their ability to trigger
receptor-mediated inositol phosphate formation in vitro.
EXPERIMENTAL PROCEDURES
Materials
Cell culture media and fetal calf serum were obtained from GIBCO-BRL
(Gaithersburg, MD) and from Intergen (Purchase, NY), respectively. Fura-2 (AM form)
was obtained fromMolecularProbes (Eugene, OR). 1251-CCK-8 (2,200 Ci/mmol) and 3H-
myo-inositol (45-80 Ci/mmol) werepurchased from New England Nuclear (Boston, MA).
Unlabelled CCK-8 (sulfated form) was obtained from Peninsula Laboratories (Belmont,
CA). L-364,718, L-365,260 and YM022 were generously provided by Wyeth Research
Ltd. (Taplow, UK). The "peptoid" compounds PD 135,158 and PD 136,450 were a gift
from Parke-Davis Research Center (Cambridge, UK).
Binding experiments
COS-7 cells (1 x 106/plate) were seeded onto 10 cm culture dishes (Costar, Cam-
bridge, MA) and grown overnight in Dulbecco's modified Eagle medium with 10 percent
fetal calf serum at 37°C. The cells were transfected with 5 ig of cDNA encoding the
human CCK-BR, cloned into the eukariotic expression vector pcDNAI. The following
day, cells were split into 24-well dishes (1 x 104/well) (Costar). After an additional 24 hr,
competition binding experiments were performed in Hank's balanced salt solution supple-
mented with 25 mM HEPES, pH 7.3, 0.2 percent bovine serum albumin and 0.15 mM
phenylmethylsulfonyl fluoride, using 20pM 1251-CCK-8 as the radioligand. After an incuba-
tion for 80 min in the absence or presence of unlabelled competitor ligands, cell mono-
layers were washed three times in Hank's balanced salt solution and then hydrolyzed in
IN NaOH fory-counting. All binding affinities (as well as signaling potencies, see below)
were calculated by computerized non-linear curve fitting using GraphPad Prizm software
(GraphPad, San Diego, CA).
Measurement of[Ca2,]i
Forty-eight hours aftertransfection with pcDNAI/CCK-BR, COS-7 cells were trypsi-
nized, suspended in modified Krebs-Ringer bicarbonate buffer, and loaded with the Ca2+
fluorophore fura-2 (30 min at 37°C). Fluorescence changes after stimulation ofcells with
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increasing concentrations of CCK-8 were determined from fluorescence emission ratios
at 340/380 nm, as previously described [22].
Measurement ofinositolphosphate accumulation
Forty-eight hours after transfection, COS-7 cells were seeded into 6-well plates (3 x
105/well) (Nunc). The cells were then pre-labelled overnight with 3 mCi/ml 3H-myo-inositol
in serum-free Dulbecco's modified Eagle medium. To assess total inositol phosphate for-
mation, the media were replaced with phosphate-buffered saline containing 10 mM LiCl,
and cells were incubated with therespective ligands for 30 min at37°C. Inositol metabolites
were extracted with methanol/chloroform; the upperphase was analyzed forinositolphos-
phates by strong anion exchange chromatography [23]. Inositol phosphateproduction was
expressed as the percent oftotal cellular tritium content incorporated during an overnight
exposure to 3H-myo-inositol.
RESULTS AND DISCUSSION
We have previously demonstrated that the recombinant human CCK-BR, when tran-
siently expressed in COS-7 cells, triggers CCK-8 induced inositol phosphate production
and Ca2+ release from intracellular stores [1]. These in vitro findings are consistent with
the well established coupling of the native CCK-BR to activation of phospholipase-C in
gastric parietal cells [24-26], suggesting that the COS cell expression systemreveals relevant
functional properties ofCCK-BRligands. Tofurtherestablishhowreceptoroccupationby an
agonistcorrelates withtheinductionofsecondmessengersignaling, weextendedourprevious
experiments by examining the concentration-effect relationship ofCCK-8 induced second
messengersignaling.Asdemonstrated as anexampleinFigure IA, nanomolarconcentrations
of CCK-8 were sufficient to fully stimulate Ca2+ release in COS-7 cells transiently
expressing the CCK-BR. Moreover, the concentration-response curve for 125I-CCK-8
binding was virtually superimposable with those for CCK-8 induced inositol phosphate
formation and intracellular Ca2+ release (Figure iB), indicating that the recombinant
CCK-BR is efficiently coupled to intracellular signaling in COS-7 cells. Therefore, this in
vitro systemprovides highfunctional sensitivity and can be utilized to detectintrinsic agonist
properties ofCCK-BR ligands.
The small synthetic CCK-BR ligands analyzed in this study included the "peptoid"
compounds, PD 135,158 and PD 136,450 [27, 28], as well as three benzodiazepine-based
ligands, L-364,718, L-365,260, and YM022 [29-31]. All ofthese compounds were able to
compete with the peptide radioligand, 1251-CCK-8, forbinding to the CCK-BR (Figure 2).
Given the close correlation between receptoroccupation and induction ofintracellular sig-
naling (see above), we used the data in Figure 2 to predict which ligand concentrations are
likely to result in full receptor activation. In general, we tested the ability of individual
compounds to trigger inositol phosphate production using a single ligand concentration
which was atleast 100-foldhigherthanrequiredfor50 percent receptoroccupation (indicated
by the corresponding IC50 values in radioligand competition experiments, see legend of
Figure 2). As an exception, the tested concentration of L-364,718 was limited to 5 ,uM.
Although this concentration is only 20-fold higher than the corresponding IC50 of L-
364,718 in binding experiments, it is still sufficient for approximately 95 percent receptor
occupation.
At maximally effective concentrations, both PD 135,158 and PD 136,450 acted as
partial agonists and stimulated inositol phosphate production to 23 ± 3 percent and
43 ± 2 percent, respectively, of the CCK-8 induced maximum (data not shown, means +
SEM from three independent experiments). The activity of these two "peptoid" ligands
was alsoconfirmed by analysis offull concentration-response curves ofCCK-BR mediated
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Figure 1A. CCK-8 triggers concentration-dependent increases of[Ca2+]; in COS-7cellsexpressing
the human CCK-BR. An aliquot from a pool of simultaneously transfected COS-7 cells was tested
at each CCK-8 concentration. No CCK-8-induced increase of[Ca2+]i was detected in untransfected
COS-7 cells (not shown).
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Figure 1B. Peak increases of[Ca2+]. (see Figure 1A), when plotted as a function ofCCK-8 con-
centration, follow a curve which is virtually superimposable with curves describing CCK-8
dependent inositol phosphate formation or receptor occupation. Receptor occupation was cal-
culated from 1251-CCK-8 competition binding studies with unlabelled CCK-8 (see Figure 2). All
data in Figure 1 show the results of a single experiment with cells transfected on the same day, and
are consistent with several replicate experiments where receptorbinding and function were assessed
on different days (e.g., data in Figures 2-4).
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Figure 2. Concentration-dependent competition ofunlabelled ligands for 125I-CCK-8 binding
to the recombinant human CCK-BR. Binding was tested with transiently transfected COS-7 cells
(see methods). Calculated IC5p values (in nM, means ± SEM ofthree independent experiments) for
peptide and "peptoid" competitiors (leftpanel) were0.09 ± 0.01 forCCK-8 (U); 0.82 ± 0.14 for PD
136,450 (-); and 2.02 ± 0.39 for PD 135,158 (0), respectively. IC50 values for non-peptide ligands
(right panel) were 0.18 ± 0.11 for YM022 (A); 6.04 ± 0.68 forL365,260 (*); and 226 ± 143 for
L-364,718 (V), respectively. Non-transfected cells showed no displaceable -25I-CCK-8 binding
(not shown).
inositol phosphate formation (Figure 3). The latter experiments revealed that the functional
potencies of PD 135,158 and of PD 136,450 were fully consistent with their respective
binding affinities (compare EC50 values in Figure 3 and IC50 values in Figure 2), again
confirming the close correlation of receptor binding and functional parameters in our in
vitro system. Interestingly, both tested "peptoid" ligands have been recently reported to
act as partial agonists in the rat and have been demonstrated by in vivo experiments to
stimulate gastric acid secretion [17] and the activity ofhistidine decarboxylase as a marker
of mucosal ECL cell density [16]. In contrast, other experiments suggested that PD
136,450 has no appreciable intrinsic activity in the rat and acts as a true antagonist ofgastric
acid secretion [19, 21] and ofgastrin-induced mucosal proliferation [20]. Furthermore, it
has been reported that "peptoid" compounds including PD 136,450 and PD 135,158
antagonized CCK-BR mediated electrophysiological responses in the rat ventromedial
hypothalamus [18].
Together, these apparently contradictory results illustrate the difficulty in classifying
CCK-BR ligands using relatively complex native tissues or in vivo models, where drug-
induced effects may depend on multiple interacting mechanisms and can be easily biased
by the choice ofexperimental conditions. Moreover, it must be also considered that ligand
function as an antagonist or as a partial agonist may heavily depend on the cellular
microenvironment where native or recombinant receptors are expressed (e.g., in gastric
parietal vs. nerve cells) and is also expected to be a function ofreceptor densities (which
may differ even between rat strains). At the receptor level, we have recently shown that
differences in drug efficacy can also result from minimal species differences in the amino
acid sequence oftheir respective CCK-BRs [32]. Considering these limitations ofcharac-
terizing drug pharmacology in animal experiments, it is important to verify the functional
341Beinborn et al.: Synthetic ligands and CCK-BR
4 PD 136,450
_ 3
2o
>~~~~~~~~~~~~
-10 -9 -8 -7 -6 -5
Peptoid concentration, log (M)
Figure 3. "Peptoid" compounds stimulate a concentration-dependent increase ofinositol phos-
phate production in COS-7 cells expressing the recombinant human CCK-BR. Respective
BC values (in nM, means ± SEM) were 0.68 ± 0.31 for PD 136,450 (0, n = 6) and 1.04 ± 0.60
foACD 135,158 (0, n = 3). Data are corrected for inositol phosphate production in the absence of
ligands (unstimulated cells), which approximated the value obtained in untransfected COS-7 cells
not expressing the human CCK-BR (not shown).
properties ofcandidate drugs in a less complex model system that eliminates a large number
of these confounding variables. In our test system, we have obtained unambiguous evi-
dence that "peptoid" compounds can, in principle, activate the human CCK-BR isoform.
Again, it is important to note that this finding, in itself, is not necessarily predictive of
overall in vivo function but rather reflects properties of "peptoid" ligands, which may
actually apply only to certain native cell types. The anticipated diversity in ligand efficacy
is exemplified by a recent report where the recombinant human CCK-BR was expressed
in CHO (instead of COS-7) cells, and the "peptoid" compound PD 135, 158 appeared to
act as a "true" antagonist (rather than as a partial agonist) [33]. In any case, knowledge of
the full spectrum of intrinsic activities to be anticipated will be a helpful guideline for
evaluating the pharmacology of"peptoid" drugs in humans.
In contrast to "peptoid" molecules, all three benzodiazepine-derived compounds
which were tested had very little, if any, ability to activate the human CCK-BR (Figure
4A). These compounds represent three generations of molecules in a promising series of
putative CCK receptor antagonists which have been developed over the past decade.
L-364,718, thederivative withlowestaffinity atthehumanCCK-BR(Figure 1), was one
ofthe first synthetically generated high affinity ligands for any peptide hormone receptor
(although it was targeted at the CCK-Areceptor subtype, rather than the CCK-BR) [12, 29].
Aderivative ofthis molecule, L-365,260, is considered the prototype CCK-BR non-peptide
antagonist and was the first synthetic ligand for this receptor with affinity in the nanomolar
range [30]. Recent efforts to further improve the affinity and receptor subtype selectivity
ofbenzodiazepine-based ligands have resulted in the synthesis ofderivatives like YM022
[31]. Consistent with its subnanomolar affinity in competititon binding experiments with
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Figure 4A. CCK-8 stimulates a concentration-dependent increase of inositol phosphate pro-
duction in COS-7 cells expressing the human CCK-BR (EC5Q = 0.15 ± 0.8 nM, mean ± SEM
of three independent experiments). In the same experiments, high concentrations of non-peptide
ligands including L-365,260 (O), L-364,718 (V) and YM022 (A) had little, if any, effect on inosi-
tol phosphate production. Data are corrected for inositol phosphate production in the absence oflig-
ands (unstimulated cells). In addition to replicate testing at a single, high concentration (K), the
effect of L-365,260 was also assessed over a broader range of concentrations (*).
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Figure 4B. Increasing concentrations ofYM022 inhibit the effect of2.5 nM CCK-8 (IC50 = 3.2
1.1 nM, n = 3). With an EC50 value of 0.15 nM for CCK-8 stimulated inositol phosphate pro-
duction (see above), the antagomst pKA value ofYM022 can be estimated at 9.69 using the "null"
method [36].
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the human CCK-BR (Figure 2) and its apparent lack of intrinsic activity (Figure 4A), we
were able to verify that YM022 acts as a high affinity antagonist and completely blocks
CCK-8 induced inositol phosphate formation (Figure 4B). As expected for a competitive
antagonist, thepA2 value ofYM022 (reflecting its functional affinity) was close toits IC50
value in competition binding experiments (compare legends ofFigures 2 and 4B).
Although, by these experiments, benzodiazepine-based ligands appearto act as "true"
antagonists and seemtohave generally different functionalproperties than "peptoid" ligands,
we have evidence thatthis distinction does not always apply. Preliminary data suggest that
even benzodiazepine-based CCK-BR ligands have inherent agonistpotential, which can be
optimized by minorchemical modifications ofthese molecules [34]. Furthermore, ligands
with similar benzodiazepine-like structure have recently been shown to act as partial or
even full agonists of the CCK-A receptor subtype, both in vivo and in vitro [35]. With
these precedents, it is likely that presently known non-peptide "antagonists" for peptide
hormone receptors, due to their inherent potential, can be systematically modified to generate
abroad range ofclinically useful agonist drugs. Equally important, these intriguing findings
should raise the awareness that apparent non-peptide "antagonists" for peptide hormone
receptors could possess residual intrinsic activity which may result in unexpected, and
possibly adverse, biological effects in the context ofcertain human diseases.
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